Cargando…

Comparison of anti-spike IgG, anti-spike IgA levels and neutralizing antibody activity induced by CoronaVac and BNT162b2 vaccines in patients with inflammatory rheumatic diseases receiving immunosuppressive therapy

BACKGROUND: The importance of COVID-19 vaccination for patients on immunosuppressive (IS) medication has increased due to the high risk of severe disease or mortality. Different vaccines have varying efficacy rates against symptomatic COVID-19, ranging from 46.8% to 95%. The objective of this study...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cosan, Fulya, Demirel, Ozlem Unay, Yalcin, Demet, Sonkaya, Muhammed Mert, Uluisik, Isilsu Ezgi, Cecen, Olida, Furuncuoglu, Yavuz, Celikmen, Deniz Maktav, Kara, Osman, Ceylan, Erkan, Avsar, Timucin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10355083/ https://www.ncbi.nlm.nih.gov/pubmed/37468956 http://dx.doi.org/10.1186/s41927-023-00342-x

Ejemplares similares

Anti-spike S1 IgA, anti-spike trimeric IgG, and anti-spike RBD IgG response after BNT162b2 COVID-19 mRNA vaccination in healthcare workers
por: Salvagno, Gian Luca, et al.
Publicado: (2021)

Coronavirus Disease 2019-Related Alterations of Total and Anti-Spike IgG Glycosylation in Relation to Age and Anti-Spike IgG Titer
por: Schwedler, Christian, et al.
Publicado: (2022)

Dynamic of humoral response to SARS-CoV-2 anti-Nucleocapsid and Spike proteins after CoronaVac vaccination
por: Bochnia-Bueno, Lucas, et al.
Publicado: (2022)

CoronaVac can induce the production of anti-SARS-CoV-2 IgA antibodies in human milk
por: Calil, Valdenise Martins Laurindo Tuma, et al.
Publicado: (2021)

Performance of the Roche/Snibe electrochemiluminescent anti-SARS-COV-2 spike assays compared to the Roche/Abbott IgG nucleocapsid and Abbott IgM spike assays
por: Lau, C.S., et al.
Publicado: (2021)

IgG Against Human Betacoronavirus Spike Proteins Correlates With SARS-CoV-2 Anti-Spike IgG Responses and COVID-19 Disease Severity
por: Wang, Jiong, et al.
Publicado: (2022)

Anti-SARS-CoV-2 spike IgG antibodies prevalence: Correspondence
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2023)

Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity and persistence of anti-SARS-CoV-2 spike antibodies
por: Vargas, Leonardo, et al.
Publicado: (2022)

One-year durability of anti-spike IgG to SARS-CoV-2: Preliminary data from the anticrown prospective observational study one year durability of COVID-19 anti-spike IgG
por: Capetti, Amedeo F., et al.
Publicado: (2021)

Neutralizing and Total/IgG Spike Antibody Responses Following Homologous CoronaVac vs. BNT162b2 Vaccination Up to 90 Days Post-Booster
por: Lau, Chin Shern, et al.
Publicado: (2022)

Anti-Spike Mucosal IgA Protection against SARS-CoV-2 Omicron Infection
por: Havervall, Sebastian, et al.
Publicado: (2022)

Identification of new drugs to counteract anti-spike IgG-induced hyperinflammation in severe COVID-19
por: Geyer, Chiara E, et al.
Publicado: (2023)

Variant-dependent oxidative and cytokine responses of human neutrophils to SARS-CoV-2 spike protein and anti-spike IgG1 antibodies
por: Almeida, Nathalie Bonatti Franco, et al.
Publicado: (2023)

Aberrant glycosylation of anti-SARS-CoV-2 spike IgG is a prothrombotic stimulus for platelets
por: Bye, Alexander P., et al.
Publicado: (2021)

Persistence of Anti-SARS-CoV-2 Spike IgG Antibodies Following COVID-19 Vaccines
por: Alharbi, Naif Khalaf, et al.
Publicado: (2022)

Subclass-switched anti-spike IgG3 oligoclonal cocktails strongly enhance Fc-mediated opsonization
por: Izadi, Arman, et al.
Publicado: (2023)

Characteristics of Vaccine- and Infection-Induced Systemic IgA Anti-SARS-CoV-2 Spike Responses
por: Norton, Natasha J., et al.
Publicado: (2023)

New-onset crescent IgA nephropathy following the CoronaVac vaccine: A case report
por: Ran, Enrong, et al.
Publicado: (2022)

Optimisation and Validation of a conventional ELISA and cut-offs for detecting and quantifying anti-SARS-CoV-2 Spike, RBD, and Nucleoprotein IgG, IgM, and IgA antibodies in Uganda
por: Oluka, Gerald Kevin, et al.
Publicado: (2023)

Evaluation of Covid-19 anti-spike IgG antibody five months after the second Covid-19 vaccination
por: Rafie, Reyhaneh Alipoor, et al.
Publicado: (2023)

Seroprevalence of SARS-CoV-2-specific anti-spike IgM, IgG, and anti-nucleocapsid IgG antibodies during the second wave of the pandemic: A population-based cross-sectional survey across Kashmir, India
por: Lone, Kouser Sideeq, et al.
Publicado: (2022)

IgA antibody dynamics in healthcare workers after CoronaVac® vaccination and heterologous Comirnaty® booster dose
por: Bochnia-Bueno, Lucas, et al.
Publicado: (2023)

Anti- IgE treatment in asthma: is atopy essential?
por: Gulec, Mustafa, et al.
Publicado: (2015)

Combined monitoring of IgG and IgA anti-Spike and anti-Receptor binding domain long term responses following BNT162b2 mRNA vaccination in Greek healthcare workers
por: Sarrigeorgiou, Ioannis, et al.
Publicado: (2022)

Evaluation of a New Spike (S)-Protein-Based Commercial Immunoassay for the Detection of Anti-SARS-CoV-2 IgG
por: Eberhardt, Kirsten Alexandra, et al.
Publicado: (2021)

Turing Universality of Weighted Spiking Neural P Systems with Anti-spikes
por: Ren, Qianqian, et al.
Publicado: (2020)

IgG and IgM antibody formation to spike and nucleocapsid proteins in COVID-19 characterized by multiplex immunoblot assays
por: Shah, Jyotsna, et al.
Publicado: (2021)

A Quantitative ELISA to Detect Anti-SARS-CoV-2 Spike IgG Antibodies in Infected Patients and Vaccinated Individuals
por: Luo, Ji, et al.
Publicado: (2022)

Spiking Neural P Systems with Membrane Potentials, Inhibitory Rules, and Anti-Spikes
por: Liu, Yuping, et al.
Publicado: (2022)

Rapid, early, and potent Spike-directed IgG, IgM, and IgA distinguish asymptomatic from mildly symptomatic COVID-19 in Uganda, with IgG persisting for 28 months
por: Serwanga, Jennifer, et al.
Publicado: (2023)

A Case of IgG and IgA Anti-Laminin-332 Antibody-Positive Mucous Membrane Pemphigoid with IgG and IgA Anti-Envoplakin and Anti-Periplakin Antibodies
por: Matsushima, Yoshiaki, et al.
Publicado: (2022)

Anti-Spike IgG in multiple sclerosis patients after BNT162b2 vaccine: An exploratory case-control study in Italy
por: Giossi, Riccardo, et al.
Publicado: (2022)

Anti‐spike IgG antibody kinetics following the second and third doses of BNT162b2 vaccine in nursing home residents
por: Jeulin, Helene, et al.
Publicado: (2022)

Risk of SARS-CoV-2 Infection in Nursing Home Residents According to COVID History and IgG Anti-Spike Antibody Levels
por: Jeulin, Helene, et al.
Publicado: (2023)

Influencing factors of anti‐SARS‐CoV‐2‐spike‐IgG antibody titers in healthcare workers: A cross‐section study
por: Reusch, Julia, et al.
Publicado: (2022)

Kinetics of dried blood spot-measured anti-SARS-CoV2 Spike IgG in mRNA-vaccinated healthcare workers
por: Puccini, Lucrezia, et al.
Publicado: (2023)

Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study
por: Barin, Burc, et al.
Publicado: (2022)

Fingolimod impairs inactivated vaccine (CoronaVac)-induced antibody response to SARS-CoV-2 spike protein in persons with multiple sclerosis
por: Türkoğlu, Recai, et al.
Publicado: (2022)

Development of a high‐sensitivity ELISA detecting IgG, IgA and IgM antibodies to the SARS‐CoV‐2 spike glycoprotein in serum and saliva
por: Faustini, Sian E., et al.
Publicado: (2021)

Activation of SARS-CoV-2 neutralizing antibody is slower than elevation of spike-specific IgG, IgM, and nucleocapsid-specific IgG antibodies
por: Takahashi, Maika, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gee1uplgh6phro1v1qeqptro8r